Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPH Cipher Pharmaceuticals	C$14.40 -3.8%	C$13.04	C$10.61 ▼ C$19.69	C$258.53M	1.2	28,465 shs	44,724 shs
CRON Cronos Group	$2.52 -3.8%	$2.06	$1.60 ▼ $2.77	$1.01B	1.01	2.66 million shs	1.77 million shs
GUD Knight Therapeutics	C$6.25 -1.6%	C$6.07	C$5.09 ▼ C$6.49	C$632.19M	0.5	64,901 shs	30,201 shs
THCX AXS Cannabis ETF	$16.60	$16.60	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPH Cipher Pharmaceuticals	-3.81%	+6.35%	+13.65%	+15.38%	+3.97%
CRON Cronos Group	-3.82%	+11.01%	+24.75%	+17.76%	+7.23%
GUD Knight Therapeutics	-1.57%	-2.34%	+2.97%	+7.76%	+10.23%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPH Cipher Pharmaceuticals	0.7336 of 5 stars	1.2	0.0	0.0	0.0	2.1	1.7	1.3
CRON Cronos Group	0.8679 of 5 stars	0.0	3.0	0.0	0.0	2.5	0.0	1.3
GUD Knight Therapeutics	1.3629 of 5 stars	2.7	0.0	0.0	0.0	1.5	1.7	0.6
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPH Cipher Pharmaceuticals	2.33	Hold	C$14.75	2.43% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
GUD Knight Therapeutics	3.33	Buy	C$7.15	14.40% Upside
THCX AXS Cannabis ETF	2.63	Moderate Buy	$16.60	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPH Cipher Pharmaceuticals	C$19.03M	13.58	C$4.08 per share	3.53	C$3.96 per share	3.64
CRON Cronos Group	$117.61M	8.22	$0.00 per share	5,630.53	$2.94 per share	0.86
GUD Knight Therapeutics	C$348.70M	1.81	C$1.62 per share	3.85	C$7.65 per share	0.82
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPH Cipher Pharmaceuticals	C$11.41M	C$0.91	15.90	∞	N/A	59.92%	17.93%	7.90%	N/A
CRON Cronos Group	$41.08M	$0.05	50.40	84.00	N/A	14.19%	-3.78%	-3.62%	N/A
GUD Knight Therapeutics	-C$30.73M	-C$0.30	N/A	∞	N/A	-8.81%	-4.04%	0.51%	N/A
THCX AXS Cannabis ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CPH, THCX, CRON, and GUD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPH Cipher Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
GUD Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	$0.72	4.34%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPH Cipher Pharmaceuticals	41.22	2.00	2.67
CRON Cronos Group	N/A	24.65	23.53
GUD Knight Therapeutics	7.52	3.36	1.79
THCX AXS Cannabis ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPH Cipher Pharmaceuticals	1.38%
CRON Cronos Group	8.71%
GUD Knight Therapeutics	12.58%
THCX AXS Cannabis ETF	N/A

Insider Ownership

Company	Insider Ownership
CPH Cipher Pharmaceuticals	42.00%
CRON Cronos Group	7.30%
GUD Knight Therapeutics	45.62%
THCX AXS Cannabis ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPH Cipher Pharmaceuticals	5	17.95 million	N/A	Not Optionable
CRON Cronos Group	450	383.81 million	355.79 million	Optionable
GUD Knight Therapeutics	725	101.15 million	N/A	Not Optionable
THCX AXS Cannabis ETF	N/A	8.50 million	N/A	Not Optionable

CPH, THCX, CRON, and GUD Headlines

Recent News About These Companies

Cannabis stocks soar on Trump reclassification speculation

August 11, 2025 | invezz.comI

Cannabis REIT IIPR Trades At A Very Low Valuation

August 10, 2025 | seekingalpha.com

Aurora Cannabis: Downgrading On Regulatory Headwinds And Competitive Pressures - Hold

August 9, 2025 | seekingalpha.com

Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

August 8, 2025 | businesswire.com

Aurora Cannabis to Host First Quarter 2026 Investor Conference Call

July 23, 2025 | prnewswire.com

Best U.S. Cannabis Penny Stocks to Trade Now â€“ July 2025 Watchlist

July 15, 2025 | marijuanastocks.comM

Pure Sunfarms Publishes First-Of-Its-Kind Cannabis Potency Research in Scientific Reports

July 15, 2025 | globenewswire.com

Christina Lake Cannabis Announces Delay in Filing its 2024 Annual Financial Statements

July 3, 2025 | globenewswire.com

THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies

June 24, 2025 | prismmediawire.comP

Aurora Cannabis Falls On Weak 2026 Outlook Despite Record Q4 Revenues

June 22, 2025 | seekingalpha.com

WM Technology Is A Good Stock For Cannabis Investors

June 22, 2025 | seekingalpha.com

Aurora Cannabis: Poland Headwinds Result In Disappointing Outlook (Rating Downgrade)

June 18, 2025 | seekingalpha.com

Aurora Cannabis: Poised For Its First Profitable Year

June 16, 2025 | seekingalpha.com

Aurora Cannabis: Underappreciated Turnaround

May 25, 2025 | seekingalpha.com

I Still Like Village Farms For Cannabis Investors Despite The Big Rally

May 19, 2025 | seekingalpha.com

Vireo Growth Inc. Announces Closing of WholesomeCo CannabisÂ & Arches Merger Transactions

May 12, 2025 | globenewswire.com

Christina Lake Cannabis Closes First Tranche of Non-Brokered Private Placement

April 30, 2025 | globenewswire.com

Have Cannabis Investors Been Early Or Wrong Or Both?

April 22, 2025 | seekingalpha.com

LEEF Brands Begins Planting Salisbury Canyon Ranch, One of the Largest Cannabis Farms in the World

April 17, 2025 | globenewswire.com

New Abacus Data Poll Reveals that Most Canadians See Cannabis as a Key Pillar of Canada's Economic Future

April 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CPH, THCX, CRON, and GUD Company Descriptions

Cipher Pharmaceuticals TSE:CPH

C$14.40 -0.57 (-3.81%)

As of 08/14/2025 04:00 PM Eastern

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

Cronos Group NASDAQ:CRON

$2.52 -0.10 (-3.82%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.50 -0.02 (-0.60%)

As of 05:20 AM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Knight Therapeutics TSE:GUD

C$6.25 -0.10 (-1.57%)

As of 08/14/2025 04:00 PM Eastern

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)

As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time